Flotillin-2: A new potential predictor for prognosis of breast cancer
Sascha Pust, first author
Overexpression of ErbB2 occurs in up to 30% of human breast cancers. ErbB2 is not down-regulated by ligand-induced mechanisms as many other receptors. In a new study now published in Oncogene (journal impact factor 6.4), Sascha Pust (photo) from Kirsten Sandvig's group at the Institute for Cancer Research and coworkers show that flotillins stabilize ErbB2 at the plasma membrane. Moreover, microarray analysis of biopsies of 194 breast cancer patients indicated that flotillin-2 is a good prognostic marker for breast cancer. Depletion of flotillins leads to internalization and degradation of ErbB2, thereby inhibiting the ErbB2-triggered signaling.
This study was a collaboration between several groups, including three groups (Sandvig, Danielsen, Liestøl) from the Center for Cancer Biomedicine (CCB).
From major journals, first or last author from the Institute for Cancer Research
Bogaard M, Strømme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, Skotheim RI, Axcrona U(2024) GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer Neoplasia, 55, 101023(in press) DOI 10.1016/j.neo.2024.101023, PubMed 38944914
Rødland GE, Temelie M, Eek Mariampillai A, Hauge S, Gilbert A, Chevalier F, Savu DI, Syljuåsen RG(2024) Potential Benefits of Combining Proton or Carbon Ion Therapy with DNA Damage Repair Inhibitors Cells, 13(12) DOI 10.3390/cells13121058, PubMed 38920686
Kurganovs NJ, Engedal N(2024) To eat or not to eat: a critical review on the role of autophagy in prostate carcinogenesis and prostate cancer therapeutics Front Pharmacol, 15, 1419806 DOI 10.3389/fphar.2024.1419806, PubMed 38910881
Bogaard M, Strømme JM, Kidd SG, Johannessen B, Bakken AC, Lothe RA, Axcrona K, Skotheim RI, Axcrona U(2024) GRIN3A: A biomarker associated with a cribriform pattern and poor prognosis in prostate cancer Neoplasia, 55, 101023(in press) DOI 10.1016/j.neo.2024.101023, PubMed 38944914
von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl RH, Mazzeo P, Schmidt N, Koch R, Hallek MJ, Chebel A, Armisen Det al.(2024) Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses Blood(in press) DOI 10.1182/blood.2023022884, PubMed 38941598
Narod SA, Gronwald J, Karlan B, Moller P, Huzarski T, Tung N, Aeilts A, Eisen A, Randall Armel S, Singer CF, Foulkes WD, Neuhausen SL, Olopade O, Pal T, Fruscio R, Metcalfe K, Raj R, Jacobson M, Sun P, Lubinski J, Kotsopoulos J(2024) Incidence of Peritoneal Cancer Following Oophorectomy among BRCA1 and BRCA2 Mutation Carriers J Natl Cancer Inst(in press) DOI 10.1093/jnci/djae151, PubMed 38937272